Long-term survival impressive for inflatable penile prostheses

Long-term survival of inflatable penile prostheses (IPPs) that havebeen in use over the past 2 decades is excellent, and thereliability of those devices appears even more promising for theenhanced models that have become more recently available, saidSteven K. Wilson, MD.

Related Videos

Related Content

Advertisement

December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 5th 2024

BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

Benjamin P. Saylor Hannah Clarke

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).

December 5th 2024

Investigators characterize safety profile of belzutifan in advanced RCC

Benjamin P. Saylor

Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.

Related Content

Advertisement

December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 5th 2024

BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

Benjamin P. Saylor Hannah Clarke

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).

December 5th 2024

Investigators characterize safety profile of belzutifan in advanced RCC

Benjamin P. Saylor

Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.